Quercetin: A pleiotropic kinase inhibitor against cancer

Cancer Treatment and Research

Volumn 159, Issue , 2014, Pages 185-205

  Russo, Gian Luigi ^a   Russo, Maria ^a   Spagnuolo, Carmela ^a   Tedesco, Idolo ^a   Bilotto, Stefania ^a   Iannitti, Roberta ^a   Palumbo, Rosanna ^a  

^a CNR   (Italy)

Author keywords

Antioxidant; Chemoprevention; Flavonoids; Kinase inhibitor; Polyphenols; Quercetin

Indexed keywords

APIGENIN; CASEIN KINASE II; DASATINIB; FAS ANTIBODY; FLAVONOL; GLYCOGEN SYNTHASE KINASE 3BETA; HEMATOPOIETIC CELL KINASE; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMATINIB; ISOQUERCITRIN; KAEMPFEROL; LUTEOLIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MYRICETIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; QUERCETIN; QUERCETIN 4' GLUCOSIDE; RAF PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RUTOSIDE; UNCLASSIFIED DRUG; ANTIOXIDANT; PROTEIN KINASE INHIBITOR;

ACUTE TOXICITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CARCINOGENICITY; CELL CYCLE ARREST; CHEMOPROPHYLAXIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; GENOTOXICITY; HUMAN; IC50; MUTAGENICITY; NEPHRITIS; NEPHROTOXICITY; NONHUMAN; OBSTRUCTIVE UROPATHY; PLEIOTROPY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; ANIMAL; DRUG EFFECT; ENZYMOLOGY; NEOPLASM; REVIEW; DRUG EFFECTS; NEOPLASMS;

ANIMALS; ANTIOXIDANTS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; QUERCETIN; SIGNAL TRANSDUCTION;

EID: 84897200764     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-38007-5_11     Document Type: Article

References (109)

1. Aksamitiene E, Kiyatkin A, Kholodenko BN (2012) Cross-talk between mitogenic Ras/ MAPK and survival PI3K/Akt pathways: a fine balance. Biochem Soc Trans 40:139–146
2. Ambrose AM, Robbins DJ, Deeds F (1952) Comparative toxicities of quercetin and quercitrin. J Am Pharm Assoc 41:119–122
3. Aziz AA, Edwards CA, Lean ME, Crozier A (1998) Absorption and excretion of conjugated flavonols, including quercetin-40-O-beta-glucoside and isorhamnetin-40-O-beta-glucoside by human volunteers after the consumption of onions. Free Radic Res 29:257–269
4. Bischoff SC (2008) Quercetin: potentials in the prevention and therapy of disease. Curr Opin Clin Nutr Metab Care 11:733–740
5. Boffetta P, Couto E, Wichmann J, Ferrari P, Trichopoulos D, Bueno-de-Mesquita HB, van Duijnhoven FJ, Buchner FL, Key T, Boeing H, Nothlings U, Linseisen J, Gonzalez CA, Overvad K, Nielsen MR, Tjonneland A, Olsen A, Clavel-Chapelon F, Boutron-Ruault MC, Morois S, Lagiou P, Naska A, Benetou V, Kaaks R, Rohrmann S, Panico S, Sieri S, Vineis P, Palli D, van Gils CH, Peeters PH, Lund E, Brustad M, Engeset D, Huerta JM, Rodriguez L, Sanchez MJ, Dorronsoro M, Barricarte A, Hallmans G, Johansson I, Manjer J, Sonestedt E, Allen NE, Bingham S, Khaw KT, Slimani N, Jenab M, Mouw T, Norat T, Riboli E, Trichopoulou A (2010) Fruit and vegetable intake and overall cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 102:529–537
6. Bokkenheuser VD, Shackleton CH, Winter J (1987) Hydrolysis of dietary flavonoid glycosides by strains of intestinal Bacteroides from humans. Biochem J 248:953–956
7. Boly R, Gras T, Lamkami T, Guissou P, Serteyn D, Kiss R, Dubois J (2011) Quercetin inhibits a large panel of kinases implicated in cancer cell biology. Int J Oncol 38:833–842
8. Boots AW, Haenen GR, Bast A (2008) Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol 585:325–337
9. Boots AW, Li H, Schins RP, Duffin R, Heemskerk JW, Bast A, Haenen GR (2007) The quercetin paradox. Toxicol Appl Pharmacol 222:89–96
10. Bors W, Heller W, Michel C, Saran M (1990) Flavonoids as antioxidants: determination of radical-scavenging efficiencies. Methods Enzymol 186:343–355
11. Boyle SP, Dobson VL, Duthie SJ, Hinselwood DC, Kyle JA, Collins AR (2000) Bioavailability and efficiency of rutin as an antioxidant: a human supplementation study. Eur J Clin Nutr 54:774–782
12. Calabrese EJ (2010) Hormesis is central to toxicology, pharmacology and risk assessment. Hum Exp Toxicol 29:249–261
13. Calabrese EJ, Blain RB (2011) The hormesis database: the occurrence of hormetic dose responses in the toxicological literature. Regul Toxicol Pharmacol 61:73–81
14. Cochet C, Feige JJ, Pirollet F, Keramidas M, Chambaz EM (1982) Selective inhibition of a cyclic nucleotide independent protein kinase (G type casein kinase) by quercetin and related polyphenols. Biochem Pharmacol 31:1357–1361
15. Conquer JA, Maiani G, Azzini E, Raguzzini A, Holub BJ (1998) Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. J Nutr 128:593–597
16. Crowe FL, Roddam AW, Key TJ, Appleby PN, Overvad K, Jakobsen MU, Tjonneland A, Hansen L, Boeing H, Weikert C, Linseisen J, Kaaks R, Trichopoulou A, Misirli G, Lagiou P, Sacerdote C, Pala V, Palli D, Tumino R, Panico S, Bueno-de-Mesquita HB, Boer J, van Gils CH, Beulens JW, Barricarte A, Rodriguez L, Larranaga N, Sanchez MJ, Tormo MJ, Buckland G, Lund E, Hedblad B, Melander O, Jansson JH, Wennberg P, Wareham NJ, Slimani N, Romieu I, Jenab M, Danesh J, Gallo V, Norat T, Riboli E (2011) Fruit and vegetable intake and mortality from ischaemic heart disease: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Heart study. Eur Heart J 32:1235–1243
17. Cunningham BD, Threadgill MD, Groundwater PW, Dale IL, Hickman JA (1992) Synthesis and biological evaluation of a series of flavones designed as inhibitors of protein tyrosine kinases. Anticancer Drug Des 7:365–384
18. D’Incalci M, Steward WP, Gescher AJ (2005) Use of cancer chemopreventive phytochemicals as antineoplastic agents. Lancet Oncol 6:899–904
19. da Silva EL, Piskula MK, Yamamoto N, Moon JH, Terao J (1998) Quercetin metabolites inhibit copper ion-induced lipid peroxidation in rat plasma. FEBS Lett 430:405–408
20. Davies SP, Reddy H, Caivano M, Cohen P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351:95–105
21. De Luca A, Maiello MR, D’Alessio A, Pergameno M, Normanno N (2012) The RAS/RAF/ MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 16(Suppl 2):S17–S27
22. Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F, Pinna LA, Ruzzene M (2005) Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ 12:668–677
23. DiDonato JA, Mercurio F, Karin M (2012) NF-kappaB and the link between inflammation and cancer. Immunol Rev 246:379–400
24. Duarte J, Perez-Palencia R, Vargas F, Ocete MA, Perez-Vizcaino F, Zarzuelo A, Tamargo J (2001) Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats. Br J Pharmacol 133:117–124
25. DuPont MS, Bennett RN, Mellon FA, Williamson G (2002) Polyphenols from alcoholic apple cider are absorbed, metabolized and excreted by humans. J Nutr 132:172–175
26. Egert S, Wolffram S, Bosy-Westphal A, Boesch-Saadatmandi C, Wagner AE, Frank J, Rimbach G, Mueller MJ (2008) Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J Nutr 138:1615–1621
27. Erlund I, Kosonen T, Alfthan G, Maenpaa J, Perttunen K, Kenraali J, Parantainen J, Aro A (2000) Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol 56:545–553
28. Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D, Baker J, Kerr DJ (1996) Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 2:659–668
29. Filipe P, Haigle J, Silva JN, Freitas J, Fernandes A, Maziere JC, Maziere C, Santus R, Morliere P (2004) Anti-and pro-oxidant effects of quercetin in copper-induced low density lipoprotein oxidation. Quercetin as an effective antioxidant against pro-oxidant effects of urate. Eur J Biochem 271:1991–1999
30. Garcia-Saura MF, Galisteo M, Villar IC, Bermejo A, Zarzuelo A, Vargas F, Duarte J (2005) Effects of chronic quercetin treatment in experimental renovascular hypertension. Mol Cell Biochem 270:147–155
31. Glossmann H, Presek P, Eigenbrodt E (1981) Quercetin inhibits tyrosine phosphorylation by the cyclic nucleotide-independent, transforming protein kinase, pp60src. Naunyn Schmiedebergs Arch Pharmacol 317:100–102
32. Goldberg DM, Yan J, Soleas GJ (2003) Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 36:79–87
33. Graefe EU, Wittig J, Mueller S, Riethling AK, Uehleke B, Drewelow B, Pforte H, Jacobasch G, Derendorf H, Veit M (2001) Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol 41:492–499
34. Granado-Serrano AB, Martin MA, Bravo L, Goya L, Ramos S (2006) Quercetin induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI-3-kinase/Akt and ERK pathways in a human hepatoma cell line (HepG2). J Nutr 136:2715–2721
35. Guerra B (2006) Protein kinase CK2 subunits are positive regulators of AKT kinase. Int J Oncol 28:685–693
36. Gugler R, Leschik M, Dengler HJ (1975) Disposition of quercetin in man after single oral and intravenous doses. Eur J Clin Pharmacol 9:229–234
37. Gulati N, Laudet B, Zohrabian VM, Murali R, Jhanwar-Uniyal M (2006) The antiproliferative effect of quercetin in cancer cells is mediated via inhibition of the PI3 K-Akt/PKB pathway. Anticancer Res 26:1177–1181
38. Hairborne JB (1993) The flavonoids advances in research since 1986. Chapman & Hall, London
39. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70
40. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674
41. Hard GC, Seely JC, Betz LJ, Hayashi SM (2007) Re-evaluation of the kidney tumors and renal histopathology occurring in a 2-year rat carcinogenicity bioassay of quercetin. Food Chem Toxicol 45:600–608
42. Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC (2007) A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 45:2179–2205
43. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D (1993) Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 342:1007–1011
44. Hirono I (1992) Is quercetin carcinogenic? Jpn J Cancer Res 83:313–314
45. Hollman PC, Katan MB (1999) Dietary flavonoids: intake, health effects and bioavailability. Food Chem Toxicol 37:937–942
46. Hollman PC, van Trijp JM, Buysman MN, van der Gaag MS, Mengelers MJ, de Vries JH, Katan MB (1997) Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man. FEBS Lett 418:152–156
47. Hollman PC, van Trijp JM, Mengelers MJ, de Vries JH, Katan MB (1997) Bioavailability of the dietary antioxidant flavonol quercetin in man. Cancer Lett 114:139–140
48. Hollman PC, vd Gaag M, Mengelers MJ, van Trijp JM, de Vries JH, Katan MB (1996) Absorption and disposition kinetics of the dietary antioxidant quercetin in man. Free Radic Biol Med 21:703–707
49. Hou DX, Kumamoto T (2010) Flavonoids as protein kinase inhibitors for cancer chemoprevention: direct binding and molecular modeling. Antioxid Redox Signal 13:691–719
50. Hwang MK, Song NR, Kang NJ, Lee KW, Lee HJ (2009) Activation of phosphatidylinositol 3-kinase is required for tumor necrosis factor-alpha-induced upregulation of matrix metalloproteinase-9: its direct inhibition by quercetin. Int J Biochem Cell Biol 41:1592–1600
51. Ito N (1992) Is quercetin carcinogenic? Jpn J Cancer Res 83:312–313
52. Johnson JL, Rupasinghe SG, Stefani F, Schuler MA, Gonzalez de Mejia E (2011) Citrus flavonoids luteolin, apigenin, and quercetin inhibit glycogen synthase kinase-3beta enzymatic activity by lowering the interaction energy within the binding cavity. J Med Food 14:325–333
53. Kelly GS (2011) Quercetin. Monograph. Altern Med Rev 16:172–194
54. Kim YH, Lee YJ (2007) TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation. J Cell Biochem 100:998–1009
55. Lamson DW, Brignall MS (2000) Antioxidants and cancer, part 3: quercetin. Altern Med Rev 5:196–208
56. Lee F, Fandi A, Voi M (2008) Overcoming kinase resistance in chronic myeloid leukemia. Int J Biochem Cell Biol 40:334–343
57. Lee J, Ebeler SE, Zweigenbaum JA, Mitchell AE (2012) UHPLC-(ESI)QTOF MS/MS profiling of quercetin metabolites in human plasma postconsumption of applesauce enriched with apple peel and onion. J Agric Food Chem 60:8510–8520
58. Lee KW, Kang NJ, Heo YS, Rogozin EA, Pugliese A, Hwang MK, Bowden GT, Bode AM, Lee HJ, Dong Z (2008) Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Res 68:946–955
59. Leonarduzzi G, Testa G, Sottero B, Gamba P, Poli G (2010) Design and development of nanovehicle-based delivery systems for preventive or therapeutic supplementation with flavonoids. Curr Med Chem 17:74–95
60. Li C, Liu X, Lin X, Chen X (2009) Structure-activity relationship of 7 flavonoids on recombinant human protein kinase CK2 holoenzyme. Zhong Nan Da Xue Xue Bao Yi Xue Ban 34:20–26
61. Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H (2009) Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release 133:238–244
62. Lionberger JM, Wilson MB, Smithgall TE (2000) Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J Biol Chem 275:18581–18585
63. Lolli G, Cozza G, Mazzorana M, Tibaldi E, Cesaro L, Donella-Deana A, Meggio F, Venerando A, Franchin C, Sarno S, Battistutta R, Pinna LA (2012) Inhibition of protein kinase CK2 by flavonoids and tyrphostins. A structural insight. Biochemistry 51:6097–6107
64. Manach C, Morand C, Crespy V, Demigne C, Texier O, Regerat F, Remesy C (1998) Quercetin is recovered in human plasma as conjugated derivatives which retain antioxidant properties. FEBS Lett 426:331–336
65. Manach C, Williamson G, Morand C, Scalbert A, Remesy C (2005) Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81:230S–242S
66. McAnlis GT, McEneny J, Pearce J, Young IS (1999) Absorption and antioxidant effects of quercetin from onions, in man. Eur J Clin Nutr 53:92–96
67. Meggio F, Pinna LA (2003) One-thousand-and-one substrates of protein kinase CK2? FASEB J 17:349–368
68. Murota K, Terao J (2003) Antioxidative flavonoid quercetin: implication of its intestinal absorption and metabolism. Arch Biochem Biophys 417:12–17
69. Nagasaka Y, Nakamura K (1998) Modulation of the heat-induced activation of mitogenactivated protein (MAP) kinase by quercetin. Biochem Pharmacol 56:1151–1155
70. Nair HB, Sung B, Yadav VR, Kannappan R, Chaturvedi MM, Aggarwal BB (2010) Delivery of antiinflammatory nutraceuticals by nanoparticles for the prevention and treatment of cancer. Biochem Pharmacol 80:1833–1843
71. Natarajan K, Manna SK, Chaturvedi MM, Aggarwal BB (1998) Protein tyrosine kinase inhibitors block tumor necrosis factor-induced activation of nuclear factor-kappaB, degradation of IkappaBalpha, nuclear translocation of p65, and subsequent gene expression. Arch Biochem Biophys 352:59–70
72. Nguyen TT, Tran E, Nguyen TH, Do PT, Huynh TH, Huynh H (2004) The role of activated MEK-ERK pathway in quercetin-induced growth inhibition and apoptosis in A549 lung cancer cells. Carcinogenesis 25:647–659
73. NTP (1992) Toxicology and carcinogenesis studies of quercetin (CAS No., 117-39-5) in F344/N rats (feed study). NTP technical report. National Toxicology Program (NTP), Research Triangle Park, North Carolina
74. Okamoto T (2005) Safety of quercetin for clinical application (review). Int J Mol Med 16:275–278
75. Olthof MR, Hollman PC, Buijsman MN, van Amelsvoort JM, Katan MB (2003) Chlorogenic acid, quercetin-3-rutinoside and black tea phenols are extensively metabolized in humans. J Nutr 133:1806–1814
76. Olthof MR, Hollman PC, Vree TB, Katan MB (2000) Bioavailabilities of quercetin-3-glucoside and quercetin-40-glucoside do not differ in humans. J Nutr 130:1200–1203
77. Peet GW, Li J (1999) IkappaB kinases alpha and beta show a random sequential kinetic mechanism and are inhibited by staurosporine and quercetin. J Biol Chem 274:32655–32661
78. Ponce DP, Maturana JL, Cabello P, Yefi R, Niechi I, Silva E, Armisen R, Galindo M, Antonelli M, Tapia JC (2011) Phosphorylation of AKT/PKB by CK2 is necessary for the AKT-dependent up-regulation of beta-catenin transcriptional activity. J Cell Physiol 226:1953–1959
79. Prior RL (2003) Fruits and vegetables in the prevention of cellular oxidative damage. Am J Clin Nutr 78:570S–578S
80. Ranawat P, Pathak CM, Khanduja KL (2012) A new perspective on the quercetin paradox in male reproductive dysfunction. Phytother Res
81. Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A (2009) Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 156:885–898
82. Russo GL (2007) Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem Pharmacol 74:533–544
83. Russo M, Palumbo R, Mupo A, Tosto M, Iacomino G, Scognamiglio A, Tedesco I, Galano G, Russo GL (2003) Flavonoid quercetin sensitizes a CD95-resistant cell line to apoptosis by activating protein kinase Calpha. Oncogene 22:3330–3342
84. Russo M, Palumbo R, Tedesco I, Mazzarella G, Russo P, Iacomino G, Russo GL (1999) Quercetin and anti-CD95(Fas/Apo1) enhance apoptosis in HPB-ALL cell line. FEBS Lett 462:322–328
85. Russo M, Spagnuolo C, Tedesco I, Bilotto S, Russo GL (2012) The flavonoid quercetin in disease prevention and therapy: facts and fancies. Biochem Pharmacol 83:6–15
86. Russo M, Spagnuolo C, Tedesco I, Russo GL (2010) Phytochemicals in cancer prevention and therapy: truth or dare? Toxins (Basel) 2:517–551
87. Ruzzene M, Pinna LA (2010) Addiction to protein kinase CK2: a common denominator of diverse cancer cells? Biochim Biophys Acta 1804:499–504
88. Santillo M, Mondola P, Seru R, Annella T, Cassano S, Ciullo I, Tecce MF, Iacomino G, Damiano S, Cuda G, Paterno R, Martignetti V, Mele E, Feliciello A, Avvedimento EV (2001) Opposing functions of Ki-and Ha-Ras genes in the regulation of redox signals. Curr Biol 11:614–619
89. Sarno S, de Moliner E, Ruzzene M, Pagano MA, Battistutta R, Bain J, Fabbro D, Schoepfer J, Elliott M, Furet P, Meggio F, Zanotti G, Pinna LA (2003) Biochemical and threedimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5, 6-dihydroindolo-(1, 2-a)quinazolin-7-yl]acetic acid (IQA). Biochem J 374:639–646
90. Scalbert A, Williamson G (2000) Dietary intake and bioavailability of polyphenols. J Nutr 130:2073S–2085S
91. Schneider H, Schwiertz A, Collins MD, Blaut M (1999) Anaerobic transformation of quercetin-3-glucoside by bacteria from the human intestinal tract. Arch Microbiol 171:81–91
92. Shirai M, Moon JH, Tsushida T, Terao J (2001) Inhibitory effect of a quercetin metabolite, quercetin 3-O-beta-D-glucuronide, on lipid peroxidation in liposomal membranes. J Agric Food Chem 49:5602–5608
93. Sicheri F, Moarefi I, Kuriyan J (1997) Crystal structure of the Src family tyrosine kinase Hck. Nature 385:602–609
94. Silberberg M, Morand C, Manach C, Scalbert A, Remesy C (2005) Co-administration of quercetin and catechin in rats alters their absorption but not their metabolism. Life Sci 77:3156–3167
95. Spagnuolo C, Russo M, Bilotto S, Tedesco I, Laratta B, Russo GL (2012) Dietary polyphenols in cancer prevention: the example of the flavonoid quercetin in leukemia. Ann N Y Acad Sci 1259:95–103
96. Spencer JP, Kuhnle GG, Williams RJ, Rice-Evans C (2003) Intracellular metabolism and bioactivity of quercetin and its in vivo metabolites. Biochem J 372:173–181
97. Spencer JP, Rice-Evans C, Williams RJ (2003) Modulation of pro-survival Akt/protein kinase B and ERK1/2 signaling cascades by quercetin and its in vivo metabolites underlie their action on neuronal viability. J Biol Chem 278:34783–34793
98. Sporn MB, Suh N (2002) Chemoprevention: an essential approach to controlling cancer. Nat Rev Cancer 2:537–543
99. Sun ZJ, Chen G, Hu X, Zhang W, Liu Y, Zhu LX, Zhou Q, Zhao YF (2010) Activation of PI3K/Akt/IKK-alpha/NF-kappaB signaling pathway is required for the apoptosis-evasion in human salivary adenoid cystic carcinoma: its inhibition by quercetin. Apoptosis 15:850–863
100. Surh YJ (2003) Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3:768–780
101. Tedesco I, Russo M, Russo GL (2010) Commentary on ‘resveratrol commonly displays hormesis: occurrence and biomedical significance’. Hum Exp Toxicol 29:1029–1031
102. Terao J, Murota K, Kawai Y (2011) Conjugated quercetin glucuronides as bioactive metabolites and precursors of aglycone in vivo. Food Funct 2:11–17
103. Torres J, Pulido R (2001) The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem 276:993–998
104. Vargas AJ, Burd R (2010) Hormesis and synergy: pathways and mechanisms of quercetin in cancer prevention and management. Nutr Rev 68:418–428
105. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP, Williams RL (2000) Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 6:909–919
106. Weng CJ, Chen MJ, Yeh CT, Yen GC (2011) Hepatoprotection of quercetin against oxidative stress by induction of metallothionein expression through activating MAPK and PI3K pathways and enhancing Nrf2 DNA-binding activity. N Biotechnol 28:767–777
107. Yao P, Nussler A, Liu L, Hao L, Song F, Schirmeier A, Nussler N (2007) Quercetin protects human hepatocytes from ethanol-derived oxidative stress by inducing heme oxygenase-1 via the MAPK/Nrf2 pathways. J Hepatol 47:253–261
108. Young JF, Nielsen SE, Haraldsdottir J, Daneshvar B, Lauridsen ST, Knuthsen P, Crozier A, Sandstrom B, Dragsted LO (1999) Effect of fruit juice intake on urinary quercetin excretion and biomarkers of antioxidative status. Am J Clin Nutr 69:87–94
109. Zhang S, Yu D (2012) Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol Sci 33:122–128